Cargando…

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase

SIMPLE SUMMARY: Cyclin-dependent kinases (CDKs) are rich and viable therapeutic targets for various cancers. The emergence of event-driven pharmacology as an alternative to occupancy-driven pharmacology has begun to address the challenges associated with selectively targeting CDKs. In this review ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rana, Sandeep, Mallareddy, Jayapal Reddy, Singh, Sarbjit, Boghean, Lidia, Natarajan, Amarnath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583118/ https://www.ncbi.nlm.nih.gov/pubmed/34771669 http://dx.doi.org/10.3390/cancers13215506

Ejemplares similares

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
por: Umfress, Alan, et al.
Publicado: (2022)

Stapling proteins in the RELA complex inhibits TNFα-induced nuclear translocation of RELA
por: Kour, Smit, et al.
Publicado: (2021)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells
por: Kour, Smit, et al.
Publicado: (2022)

Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth
por: Napoleon, John Victor, et al.
Publicado: (2022)

Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase
por: Choi, Eungi, et al.
Publicado: (2018)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

PROTACs: The Future of Leukemia Therapeutics
por: Anwar, Zubair, et al.
Publicado: (2022)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues
por: Yamanaka, Satoshi, et al.
Publicado: (2022)

Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery
por: Kolluru, Srikanth, et al.
Publicado: (2019)

Small molecule induced polymerization of BCL6 facilitates SIAH1 mediated degradation
por: Rana, Sandeep, et al.
Publicado: (2021)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
por: Słabicki, Mikołaj, et al.
Publicado: (2020)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Therapeutic targeting of transcriptional cyclin-dependent kinases
por: Galbraith, Matthew D., et al.
Publicado: (2018)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease
por: Guardigni, Melissa, et al.
Publicado: (2023)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Cyclin E1 regulates hematopoietic stem cell quiescence
por: Jayapal, Senthil Raja, et al.
Publicado: (2013)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Fibrin glue in ophthalmology
por: Panda, Anita, et al.
Publicado: (2009)

DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation
por: Mullen, Nicholas J., et al.
Publicado: (2023)

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
por: Wang, Chao, et al.
Publicado: (2022)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Large fundal varices: to glue or not to glue?
por: Mohiuddin, Syed Adnan, et al.
Publicado: (2014)

PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
por: Adhikari, Bikash, et al.
Publicado: (2020)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
por: Sachkova, Anastasia A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ra46srqpnb3r61c8djcu7jovci